09/25/2015 // JusticeNewsFlash // (press release)
Canada – A class-action lawsuit is being pursued over the diabetes drug Avandia. As reported by CBCNews.ca, lawyers in Nova Scotia have requested that a class action be certified against GlaxoSmithKline, alleging that their diabetes drug is defective.
As noted in the report, if the action is successful, it would be the first class-action suit allowed to proceed, despite other lawsuits previously being initiated. In accordance with Nova Scotia law, the action is required to be certified as a class action prior to moving forward.
Attorney Ray Wagner is quoted as writing in his court brief “The plaintiffs allege that Avandia is defective or unfit and that the defendants failed to adequately warn Canadians about the risk of CV (cardio vascular) events caused by Avandia.”
The lawsuit names two individuals as representative plaintiffs. One of the plaintiffs alleges that he was prescribed Avandia and took it for five years. He was reportedly diagnosed with congestive heart failure after stopping the medication.
Lawyers for GlaxoSmithKline wrote in a brief “All treatment options have risks and benefits… Patients with Type 2 diabetes usually have other medical problems and are susceptible to cardiovascular problems, including heart attack.”
More stories related to Product Liability Complaints /?s=product+liability+complaints